Endovia Health Sciences, Inc.EDVA
Price (close)
$0.19
Market cap
—
P/E
—
Revenue (TTM)
$32,090
Net income
-$17.3M
Dividend yield
—
1-year total return
-97.8%
Net margin
-53856.5%
Revenue growth
101.8%
Debt / equity
—
What Endovia Health Sciences, Inc. does.
to manage brands across viable growth segments within the consumer beverage industry. As a result of our lack of capital, we did not generate
revenue from February 2025 until March 2026 when we delivered tequila as described below. Our beverage operations have historically not
been profitable. Because of our lack of capital to generate revenue, our management reviewed strategic alternatives inside and outside
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $11.3M | $18.1M | $18.9M | $801,273 | $73,066 |
| Net income | -$28.7M | -$29.1M | -$21.7M | -$21.0M | -$23.8M | -$25.2M |
| Free cash flow | -$21.4M | -$14.7M | -$14.1M | -$10.2M | -$7.3M | — |
More on EDVA.
- Endovia Health Sciences, Inc. summary
- Endovia Health Sciences, Inc. financial statements
- Endovia Health Sciences, Inc. key metrics
- Endovia Health Sciences, Inc. health scores and style box
- Endovia Health Sciences, Inc. earnings
- Endovia Health Sciences, Inc. dividends
- Endovia Health Sciences, Inc. valuation
- Endovia Health Sciences, Inc. ownership and insiders
- Endovia Health Sciences, Inc. peers
Figures from Endovia Health Sciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.